Pancoast tumor classification: Difference between revisions
Jump to navigation
Jump to search
Mazia Fatima (talk | contribs) Created page with "__NOTOC__ {{Pancoast tumor}} {{CMG}}; {{AE}} ==Overview== There is no established system for the classification of [disease name]. OR [Disease name] may be classified acco..." |
Mazia Fatima (talk | contribs) |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
The staging of [[malignant]] insulinoma being a [[pancreatic neuroendocrine tumor]] may be classified into several subtypes based on [[American Joint Committee on Cancer|American Joint Cancer Committee]] ([[AJCC]]) 7th edition 2010: <ref name="pmid27646952">{{cite journal| author=Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C et al.| title=Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. | journal=J Clin Oncol | year= 2017 | volume= 35 | issue= 3 | pages= 274-280 | pmid=27646952 | doi=10.1200/JCO.2016.67.8193 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27646952 }} </ref><ref name="pmid25816036">{{cite journal| author=Yang M, Zeng L, Zhang Y, Wang WG, Wang L, Ke NW et al.| title=TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. | journal=Medicine (Baltimore) | year= 2015 | volume= 94 | issue= 12 | pages= e660 | pmid=25816036 | doi=10.1097/MD.0000000000000660 | pmc=4554009 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25816036 }} </ref> | |||
{| class="wikitable" align="right" | |||
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Stage''' | |||
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''T''' | |||
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''N''' | |||
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''M''' | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |IA | |||
| style="background:#F5F5F5;" + |T1 | |||
| style="background:#F5F5F5;" + |N0 | |||
| style="background:#F5F5F5;" + |M0 | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |IB | |||
| style="background:#F5F5F5;" + |T2 | |||
| style="background:#F5F5F5;" + |N0 | |||
| style="background:#F5F5F5;" + |M0 | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |IIA | |||
| style="background:#F5F5F5;" + |T3 | |||
| style="background:#F5F5F5;" + |N0 | |||
| style="background:#F5F5F5;" + |M0 | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |IIB | |||
| style="background:#F5F5F5;" + |T1-3 | |||
| style="background:#F5F5F5;" + |N1 | |||
| style="background:#F5F5F5;" + |M0 | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |III | |||
| style="background:#F5F5F5;" + |T4 | |||
| style="background:#F5F5F5;" + |Any N | |||
| style="background:#F5F5F5;" + |M0 | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |IV | |||
| style="background:#F5F5F5;" + |Any T | |||
| style="background:#F5F5F5;" + |Any N | |||
| style="background:#F5F5F5;" + |M1 | |||
|} | |||
{| class="wikitable" align="center" | |||
| colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''AJCC 2010''' | |||
|- | |||
! rowspan="4" style="background:#DCDCDC;" align="center" + | T | |||
| style="background:#DCDCDC;" align="center" + | T1 | |||
| style="background:#F5F5F5;" + |<2 cm in greatest dimension | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |T2 | |||
| style="background:#F5F5F5;" + |>2 cm in greatest dimension | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |T3 | |||
| style="background:#F5F5F5;" + |Beyond the [[pancreas]] but without involvement of the [[superior mesenteric artery]] | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |T4 | |||
| style="background:#F5F5F5;" + |Involvement of the ''[[celiac axis]]'' or [[superior mesenteric artery]] (unresectable [[tumor]]) | |||
|- | |||
! rowspan="2" style="background:#DCDCDC;" align="center" + | N | |||
| style="background:#DCDCDC;" align="center" + |N0 | |||
| style="background:#F5F5F5;" + |No regional [[lymph node]] [[metastasis]] | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |N1 | |||
| style="background:#F5F5F5;" + |Regional [[lymph node]] [[metastasis]] | |||
|- | |||
! rowspan="2" style="background:#DCDCDC;" align="center" + | M | |||
| style="background:#DCDCDC;" align="center" + |M0 | |||
| style="background:#F5F5F5;" + |No distant [[metastasis]] | |||
|- | |||
| style="background:#DCDCDC;" align="center" + |M1 | |||
| style="background:#F5F5F5;" + |Distant [[metastasis]] | |||
|- | |||
|} | |||
There is no established system for the classification of [disease name]. | There is no established system for the classification of [disease name]. | ||
Revision as of 23:48, 19 February 2018
|
Pancoast tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancoast tumor classification On the Web |
|
American Roentgen Ray Society Images of Pancoast tumor classification |
|
Risk calculators and risk factors for Pancoast tumor classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
The staging of malignant insulinoma being a pancreatic neuroendocrine tumor may be classified into several subtypes based on American Joint Cancer Committee (AJCC) 7th edition 2010: [1][2]
| Stage | T | N | M |
| IA | T1 | N0 | M0 |
| IB | T2 | N0 | M0 |
| IIA | T3 | N0 | M0 |
| IIB | T1-3 | N1 | M0 |
| III | T4 | Any N | M0 |
| IV | Any T | Any N | M1 |
| AJCC 2010 | |||
| T | T1 | <2 cm in greatest dimension | |
|---|---|---|---|
| T2 | >2 cm in greatest dimension | ||
| T3 | Beyond the pancreas but without involvement of the superior mesenteric artery | ||
| T4 | Involvement of the celiac axis or superior mesenteric artery (unresectable tumor) | ||
| N | N0 | No regional lymph node metastasis | |
| N1 | Regional lymph node metastasis | ||
| M | M0 | No distant metastasis | |
| M1 | Distant metastasis | ||
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
- There is no established system for the classification of [disease name].
OR
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [Group1]
- [Group2]
- [Group3]
- [Group4]
OR
- [Disease name] may be classified into [large number > 6] subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
- [Disease name] may be classified into several subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
OR
- Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
- If the staging system involves specific and characteristic findings and features:
- According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
- The staging of [malignancy name] is based on the [staging system].
OR
- There is no established system for the staging of [malignancy name].
References
- ↑ Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C; et al. (2017). "Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems". J Clin Oncol. 35 (3): 274–280. doi:10.1200/JCO.2016.67.8193. PMID 27646952.
- ↑ Yang M, Zeng L, Zhang Y, Wang WG, Wang L, Ke NW; et al. (2015). "TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution". Medicine (Baltimore). 94 (12): e660. doi:10.1097/MD.0000000000000660. PMC 4554009. PMID 25816036.